Annual Drug Patent Expirations for REMODULIN
Remodulin is a drug marketed by United Therap and is included in two NDAs. It is available from one supplier. There are ten patents protecting this drug and two Paragraph IV challenges.
Drug patent litigation for REMODULIN.
This drug has sixty-four patent family members in ten countries.
The generic ingredient in REMODULIN is treprostinil. One supplier is listed for this compound. Additional details are available on the treprostinil profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
